Search results for: 'pace pace analysis for laboratory develop'

Qualified respondents to this Frost & Sullivan survey were invited to participate in a telephone interview examining their laboratory s product purchasing process in 2023 and expectations for 2024. Frost & Sullivan has conducted similar studies among the same targeted respondents since 2012. The survey provides companies with actionable and trendin...

This Frost Radar for the laboratory information management systems (LIMS) industry benchmarks providers offering workflow management and paperless tracking capabilities to help improve process efficiencies for life sciences companies. LIMS have several functionalities, such as obtaining, storing, managing, retrieving, and recording laboratory data...

With persistent geopolitical tensions and the resultant trade fragmentation continuing to shape the global economy, policy priorities among countries advanced and emerging are shifting toward macroeconomic frameworks that will insulate them from external shocks. Incremental reforms that support sustainability and Industry 5.0 practices will have pr...

Immuno-oncology (I-O) therapies target tumors by harnessing the host s immune system. With the growing incidence and prevalence of various types of aggressive and refractory cancers, the next-generation I-O therapy pipeline has witnessed significant growth. Chimeric antigen receptor (CAR)-T cell therapy and tumor-targeted antibody therapies, includ...

Electronic devices are an integral part of human life, serving a multitude of functionalities. Many application areas for example, electronic gadgets, health monitoring and medical devices, activity tracking, smart cards, and wearable electronics require lightweight, flexible, and compact energy storage solutions. The focus on miniaturization and c...

By 2023, biologics constituted 44% of the therapeutic pipeline, with antibodies and recombinant proteins as leading categories. Nevertheless, advancements in these fields decelerated, with most of the expansion happening in heterologous cell treatments, synthetic nucleic acids, and viruses. The global biologics pipeline will shift toward more compl...

The global pharmaceutical research and development (R&D) pipeline accounts for more than 21,000 molecules, as of April 2023, indicating a 5.8% hike over 2022, with more than 6,100 molecules in active development. In general, however, the pharma/biopharma industry has stagnated with respect to R&D activity. Overall R&D expenditure totals about $276....

According to the International Energy Agency (IEA), the aviation industry accounts for 2% of global carbon emissions. Total cumulative emissions reached approximately 800 million tons in 2022, and cumulative emissions are expected to reach approximately 1,750-2,000 million tons by 2050. The International Air Transport Association (IATA) has committ...

The International Energy Agency (IEA) estimates that emissions from the energy sector alone reached 37 gigatonnes (Gt) of carbon dioxide (CO2) in 2022, hitting a new milestone. Mitigating greenhouse gases (GHGs) and achieving long-term net-zero energy targets are focal points for several developed and developing countries. However, the defossilizat...